Skip to content

TO · SZLS.TO · MEDICAL - DIAGNOSTICS & RESEARCH

StageZero Life Sciences Ltd.

$0.04as of 2026-11-13 · Mkt cap 4.94M

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Healthcare · Medical - Diagnostics & Research Richmond Hill, ON L4B 3B2 stagezerolifesciences.com

How the business is doing

Fiscal 2008–2022, USD

Revenue
$3.8M+56.1% 5y CAGRd
20082022
Net income
-$-11.42M
20082022
Free cash flow
-$-3.53M
20082022
Total equity
-$-7.5M
20082022

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About StageZero Life Sciences Ltd.

        StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.

        CEO
        James R. Howard-Tripp
        Employees
        40
        Beta
        0.45

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.